stockrowPraxis Precision Medicines, Inc.
PRAX Healthcare Biotechnology
Praxis Precision Medicines, Inc.’s revenue for fiscal 2024 (year ended December 2024) was $8.6 million, up 249.5% from fiscal 2023.
- Revenue
- +1,349.1%
- EPS
- +13.3%
- Free cash flow
- −43.5%
Quarter to June 2026, against a year earlier
Follow PRAX
Alert me
Praxis Precision Medicines, Inc. (PRAX) Operating cash flow
Praxis Precision Medicines, Inc.'s operating cash flow for fiscal 2025 was −$249.1M, compared with −$131.8M in fiscal 2024. Over the twelve months to 30 June 2026 it was −$305.1M. Over the past ten years it has ranged from −$249.1M (fiscal 2025) to −$20.7M (fiscal 2018) — the current reading is the lowest in ten years. Praxis Precision Medicines, Inc. ranks 570th of 603 Biotechnology companies by operating cash flow.
Operating cash flow, annual
Embed this chart
Annual newest first
| Period | Operating cash flow | Change |
|---|---|---|
| FY2025 | −$249.1M | — |
| FY2024 | −$131.8M | — |
| FY2023 | −$111.1M | — |
| FY2022 | −$185.0M | — |
| FY2021 | −$124.6M | — |
| FY2020 | −$52.6M | — |
| FY2019 | −$33.4M | — |
| FY2018 | −$20.7M | — |
Quarterly newest first
| Period | Operating cash flow | Change |
|---|---|---|
| Jun 2026 | −$77.5M | — |
| Mar 2026 | −$86.2M | — |
| Dec 2025 | −$76.3M | — |
| Sep 2025 | −$65.1M | — |
| 25 more quarters | Free account |
Against its own ten years
Operating cash flow against peers
| Company | Operating cash flow |
|---|---|
| KRYS Krystal Biotech, Inc. compare | $323.9M |
| CORT Corcept Therapeutics Incorporated compare | $198.1M |
| ARWR Arrowhead Pharmaceuticals, Inc. compare | −$59.1M |
| AXSM Axsome Therapeutics, Inc. compare | −$81.8M |
| RYTM Rhythm Pharmaceuticals, Inc. compare | −$81.8M |
| ABVX Abivax SA Sponsored ADR compare | −$225.9M |
| SYRE Spyre Therapeutics, Inc. compare | −$249.3M |
| PRAX Praxis Precision Medicines, Inc. | −$305.1M |
| CYTK Cytokinetics, Incorporated compare | −$572.0M |
What Operating cash flow is
Operating Cash Flow shows how much cash a company’s day-to-day business actually brings in, after paying suppliers, staff and taxes.
Reported line item